Solorank.ai
Login

Cached score snapshot

US.WST · West Pharmaceutical Services

110分制 62.9/110；5D動能v2 3/50；排序分 65.9/160

Back to ranking Open volume snapshot
Ranking score 65.9/160
Main score 62.9/110
5D momentum v2 3/50
Rank #187
Setup grade F 26.3

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 26.3 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-22 07-17 08-26 09-14 09-29 $300.54$356.32$412.09 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.509 · anchors 120 +0.90% -1.65% / +2.78% 57.5% 1.3% Actual +1.87% · vs median +0.97% · inside 25-75 band
30D observation +8.41% +3.64% / +13.96% 82.5% 3.8% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.70% -1.45% / +2.20% 57.5% 1.3% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-05-22 → 2026-09-29 · 145 archived points · 3 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 65.9
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 62.9/110 (觀望)
5D momentum v2 3/50 (弱)
Score with momentum v2 65.9/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 346.1655
ma50 346.321
close 346.59
prevClose 346.61
avgVolume20 740917
volumeRatio 0.26
changePercent -0.01

Metrics snapshot

close 346.59
volume 189240
changePercent -0.01

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 62.9/110
Main rating 觀望
5D momentum v2 3/50
Score with momentum v2 65.9/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.2/5 · 一般
Dimension score 3.2/5
Dimension grade 一般

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.6
debtPoints 0.5
marginPoints 0.4
turnoverUsdM 65.5887
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 10.8/20 · 較差
Dimension score 10.8/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 3.2
obvPoints 1.6
vwapPoints 3.2

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.WST
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 12.2/15 · 優秀
Dimension score 12.2/15
Dimension grade 優秀

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 15.19

trend

score 3.4

details

qqq

ma20 706.243
ma50 712.9844
name QQQ
close 717.51
points 1.4

spy

ma20 758.684
ma50 749.836
name SPY
close 767.45
points 2
source twelvedata+fred
atrPct 1.9063
atrPoints 4
cciPoints 2.4
vixPoints 2.4
marketTrendPoints 3.4

催化劑 — 6/20 · 較差
Dimension score 6/20
Dimension grade 較差

Sub-items

catalyst

score 6

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 1
catalystPoints 6

風險管理 — 7.4/10 · 良好
Dimension score 7.4/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 1.9063
turnoverUsdM 65.5887
liquidityPoints 0.4
volatilityPoints 1.2
rrPoints 1.4

stopLevels

symbol US.WST
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 333.3758

strength_details

ma_score 1
atr_score 2.5
rsi_score 3
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.3
stop_loss_percent 3.8
take_profit_price 363.9195
target_multiplier 1.9
technical_strength 1.75
take_profit_percent 5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.3114
stopLossPercent 3.8126
diversificationPoints 2

技術信號 — 17.3/30 · 較差
Dimension score 17.3/30
Dimension grade 較差

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 1
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1
vcp_reason 跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N

vcp_metrics

up_days 4
vol_ref 726833.3333
down_days 5
vcp_ready false
above_ma50 true
avg_vol_10 480260
avg_vol_20 769090
avg_vol_30 726833.3333
range_pct_10 0.0458
range_pct_20 0.1752
range_pct_30 0.1752
up_expand_ok false
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok true
up_expand_days 0
breakout_20d_ok false
vol_ratio_10_30 0.6608
dist_to_20d_high 0.1021
down_shrink_days 4
breakout_level_20d 386
vcp_breakout_confirm false
contraction_ratio_10_30 0.2617
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 0.8
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 1
volumePointsTechnical 0.4

情緒分析 — 6/10 · 一般
Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 5
sentimentScoreRaw 1.5

sentimentData

raw {"id":141209552,"url":"https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.","category":"company","datetime":1786643280,"headline":"WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"}, {"id":141209369,"url":"https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.","category":"company","datetime":1786643280,"headline":"Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"}, {"id":141209368,"url":"https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.","category":"company","datetime":1786643280,"headline":"WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"}, {"id":141202470,"url":"https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...","category":"company","datetime":1786518635,"headline":"West (WST) Stock Looks Overvalued After A 47% One Year Run"}, {"id":141135724,"url":"https://finnhub.io/api/news?id=8e4664598d306ae1ef59232b19e85e05ac357109829847b04453f423292922d6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]","category":"company","datetime":1786024529,"headline":"Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2"}, {"id":141105188,"url":"https://finnhub.io/api/news?id=8445c0043c52e4322380ebeeeaf25c5b1f27d7b1521d55b5c046a500753c77ad","image":"","source":"Fintel","related":"WST","summary":"","category":"company","datetime":1785810547,"headline":"West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03"}, {"id":141097112,"url":"https://finnhub.io/api/news?id=ed7760005858daa2fb47089e589aba505882a88fd96abb4b0157752c40e9e312","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...","category":"company","datetime":1785733722,"headline":"Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?"}, {"id":141097113,"url":"https://finnhub.io/api/news?id=3672b37da6f185069441e06aab66c46e1ec0c85928bdd57eb6c303fe26995654","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services (WST) has drawn fresh investor attention after reporting second quarter results that exceeded expectations and raising full year revenue and adjusted earnings guidance, supported by demand for biologics and biosimilars related products. See our latest analysis for West Pharmaceutical Services. The share price has been volatile in recent months, with a 13.4% 90 day share price return and 23.4% year to date share price return, but a 6.6% decline over 30 days as...","category":"company","datetime":1785731538,"headline":"West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?"}
raw_source {"id":141209552,"url":"https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.","category":"company","datetime":1786643280,"headline":"WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"}, {"id":141209369,"url":"https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.","category":"company","datetime":1786643280,"headline":"Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"}, {"id":141209368,"url":"https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.","category":"company","datetime":1786643280,"headline":"WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"}, {"id":141202468,"url":"https://finnhub.io/api/news?id=d0e7e846d43e052f5cf2cc75222b2e19cdf44371cf038926785d5e1b34db15a4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.","category":"company","datetime":1786549260,"headline":"Here's Why You Should Add BrightSpring Stock to Your Portfolio Now"}, {"id":141202469,"url":"https://finnhub.io/api/news?id=e0277f3fb832d7629b5cfa40809a7c12d4b0dd92ab901d8e20bba9889d3940ae","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.","category":"company","datetime":1786548120,"headline":"NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up"}, {"id":141202470,"url":"https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...","category":"company","datetime":1786518635,"headline":"West (WST) Stock Looks Overvalued After A 47% One Year Run"}, {"id":141202034,"url":"https://finnhub.io/api/news?id=c70632c2f9259acf971a4ff2e21f3a79f70231e7041cbbc36844dbb90356e0cf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.","category":"company","datetime":1786465260,"headline":"CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up"}, {"id":141202035,"url":"https://finnhub.io/api/news?id=5b2009080943f484ca312cf2ddae85582953343181666e7127ac9f3833e34b70","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.","category":"company","datetime":1786461600,"headline":"RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised"}, {"id":141177784,"url":"https://finnhub.io/api/news?id=2b214d626c55d69f3321fcb009f6866c20e2d848f4d640c809751929b9c57eb4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.","category":"company","datetime":1786380840,"headline":"Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut"}, {"id":141176776,"url":"https://finnhub.io/api/news?id=51215d10973a1d3873da231aeeefd48c6bc09a21e18da33bfd7c86363e77526d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.","category":"company","datetime":1786379820,"headline":"iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised"}, {"id":141164828,"url":"https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.","category":"company","datetime":1786243803,"headline":"Top 50 High-Quality Dividend Growth Stocks For August 2026"}, {"id":141153743,"url":"https://finnhub.io/api/news?id=480497e730b8ea5e3d057667533cf1edc2347a0cb1c86eb68ed0787f76b9527b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Management put a much higher number on its future, and the stock has been on a tear ever since. But is this a fleeting AI boom or a fundamental rewiring of the business.","category":"company","datetime":1786139750,"headline":"Cisco Stock Is Finally Pricing In A New Growth Story"}, {"id":141151192,"url":"https://finnhub.io/api/news?id=fc7d6e4a19b1ecefa500bbfc8e2e25de6b5c94dd43bc59e1620796a4007a8a89","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.","category":"company","datetime":1786127700,"headline":"XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales"}, {"id":141149609,"url":"https://finnhub.io/api/news?id=328e13ad11d15da6764538592fc4d871018f1a757eb98788f0e82e7cddc1f178","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.","category":"company","datetime":1786121220,"headline":"AMN Q2 Earnings Beat Estimates on Staffing and Search Growth, Stock Up"}, {"id":141149610,"url":"https://finnhub.io/api/news?id=8e5bd7fa2a58cd02c146fd34fccaed30767229053dcd7376a68126d672047d2f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.","category":"company","datetime":1786120560,"headline":"DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up"}, {"id":141140628,"url":"https://finnhub.io/api/news?id=a8b9dcae545cc5c62870f85c5a89bc5758dc075833203dde38abaea6245b92f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.","category":"company","datetime":1786035840,"headline":"PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut"}, {"id":141137316,"url":"https://finnhub.io/api/news?id=f23c7f57565c87589923985dcfb23a36115479fe932f711cc0df05b80818daf2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.","category":"company","datetime":1786033860,"headline":"LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised"}, {"id":141137317,"url":"https://finnhub.io/api/news?id=800e586663a06c21846fb4704cde171e522540f493e9141574d3def76d3d7334","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.","category":"company","datetime":1786030860,"headline":"MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised"}, {"id":141135724,"url":"https://finnhub.io/api/news?id=8e4664598d306ae1ef59232b19e85e05ac357109829847b04453f423292922d6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]","category":"company","datetime":1786024529,"headline":"Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2"}, {"id":141125909,"url":"https://finnhub.io/api/news?id=4cc57192c03dfc0eedad44bf9d950f4c8edb9fb26d63e7e6f813fcb1fdc036e2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.","category":"company","datetime":1785952920,"headline":"Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?"}, {"id":141124354,"url":"https://finnhub.io/api/news?id=3c99f0ca4df1360198bfda8776337250d51ac456a32bc832bac0b78ca6f14858","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Hinge Health's Q2 revenues jump 53% as stronger member yield, margin gains and raised 2026 guidance reinforce business momentum.","category":"company","datetime":1785948000,"headline":"HNGE Q2 Earnings Meet Estimates, Sales Top, '26 View Raised, Stock Up"}, {"id":141122656,"url":"https://finnhub.io/api/news?id=026d8fb37247e734556ab139d7617d44722f4e154e1c54607e4041ad152a13a1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.","category":"company","datetime":1785941400,"headline":"COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised"}, {"id":141122657,"url":"https://finnhub.io/api/news?id=d65126c035551814d108e50a1313d81a1237d5b5ba6733964cc3b8dad767605a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.","category":"company","datetime":1785941340,"headline":"FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand"}, {"id":141114964,"url":"https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.","category":"company","datetime":1785870540,"headline":"RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"}, {"id":141112034,"url":"https://finnhub.io/api/news?id=29220b2023579682d098f84e1a9bd930eeb6b970fa72c6152de3c809aefed06f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.","category":"company","datetime":1785862680,"headline":"Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up"}, {"id":141105188,"url":"https://finnhub.io/api/news?id=8445c0043c52e4322380ebeeeaf25c5b1f27d7b1521d55b5c046a500753c77ad","image":"","source":"Fintel","related":"WST","summary":"","category":"company","datetime":1785810547,"headline":"West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03"}, {"id":141102471,"url":"https://finnhub.io/api/news?id=30596f6493c7617c08324dee7f0bc7938ac6cda5b78e1147447672994f261dbc","image":"","source":"Benzinga","related":"WST","summary":"Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.","category":"company","datetime":1785768764,"headline":"Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412"}, {"id":141097112,"url":"https://finnhub.io/api/news?id=ed7760005858daa2fb47089e589aba505882a88fd96abb4b0157752c40e9e312","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...","category":"company","datetime":1785733722,"headline":"Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?"}, {"id":141097113,"url":"https://finnhub.io/api/news?id=3672b37da6f185069441e06aab66c46e1ec0c85928bdd57eb6c303fe26995654","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services (WST) has drawn fresh investor attention after reporting second quarter results that exceeded expectations and raising full year revenue and adjusted earnings guidance, supported by demand for biologics and biosimilars related products. See our latest analysis for West Pharmaceutical Services. The share price has been volatile in recent months, with a 13.4% 90 day share price return and 23.4% year to date share price return, but a 6.6% decline over 30 days as...","category":"company","datetime":1785731538,"headline":"West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?"}, {"id":141087819,"url":"https://finnhub.io/api/news?id=440ad6f9856caed08f8f38e51aff99b0e745775dcc353978de6ea663dfb2602f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the compan","category":"company","datetime":1785596397,"headline":"The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call"}, {"id":141086424,"url":"https://finnhub.io/api/news?id=3a243f9a49b7b9f0ce5ee608668ded9b9c22573de813e7bfe8c1d840a90af833","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.","category":"company","datetime":1785575757,"headline":"3 Reasons to Avoid WST and 1 Stock to Buy Instead"}, {"id":141084159,"url":"https://finnhub.io/api/news?id=b01254886ca04bb4ee2ca13216638f12f5b9bc0c9bbe991af37b4d7b45adc14c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read now.","category":"company","datetime":1785532692,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week August 2"}, {"id":141080482,"url":"https://finnhub.io/api/news?id=3b0428d64cc3da400032a5c5321ae5b4192319def2ec16d669798ecea40d5a20","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.","category":"company","datetime":1785516717,"headline":"3 Cash-Heavy Stocks We Approach with Caution"}, {"id":141080381,"url":"https://finnhub.io/api/news?id=c1245c5746c22ff46ef9ac1ca560e75935767219c3b020b02059cac810c7e881","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.","category":"company","datetime":1785510480,"headline":"MMSI Q2 Earnings & Revenues Beat Estimates, '26 Guidance Raised"}, {"id":141079192,"url":"https://finnhub.io/api/news?id=ba7731a4b95a73e9b539fb9155adffe31e1dea22943a4c45be8f8fa12e57990b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.","category":"company","datetime":1785504720,"headline":"Resmed's Q4 Earnings on Deck: What's in Store for the Stock?"}, {"id":141079102,"url":"https://finnhub.io/api/news?id=693d7da201dd6ee1737f170709fd5edad838d6fb56b43a75a77dcfa9ba5d0007","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.","category":"company","datetime":1785504660,"headline":"SYK Falls Despite Q2 Earnings Beat on Strong Sales and Cyber Recovery"}, {"id":141077645,"url":"https://finnhub.io/api/news?id=5714fc9c6779de656a4e2a6b8b9d2ce3f672f1d8914a60d2ed397cf1fb5e57a1","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205618145/image_2205618145.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.","category":"company","datetime":1785487080,"headline":"Conestoga SMid Cap Composite Q2 2026 Portfolio Review"}, {"id":141068411,"url":"https://finnhub.io/api/news?id=0007ffe0216e700b6c8ed0b3e1049e7206b7730a714da3b4daae9f8b75ec010f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.","category":"company","datetime":1785427320,"headline":"BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract"}, {"id":141068412,"url":"https://finnhub.io/api/news?id=cc292e3b8f12ff007275fcb1af654d34bc6fe0a8a71b1d867b4bfd95cdd330fc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.","category":"company","datetime":1785426900,"headline":"Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up"}, {"id":141059588,"url":"https://finnhub.io/api/news?id=67311e2187c8daa5f97909344e3c76b99fbde905a77e989bccdfea2563d55757","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225310528/image_2225310528.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"NOBL beats SPY YTD in 2026; explore 25 undervalued Dividend Aristocrats with 10%+ projected returns and fresh dividend hikes—see the list now.","category":"company","datetime":1785354040,"headline":"Best Dividend Aristocrats For August 2026"}, {"id":141055862,"url":"https://finnhub.io/api/news?id=d2c593c9349957b3ca16152323c967c4417d3ab3f9db8797978f488a55bb6f6e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.","category":"company","datetime":1785339720,"headline":"GEHC Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market"}, {"id":141055863,"url":"https://finnhub.io/api/news?id=dc6b208f3d8cb61b19b3c297a8cc56c2951996a4af7af738c66e92cd98982229","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.","category":"company","datetime":1785337380,"headline":"Here's Why You Should Retain DaVita Stock in Your Portfolio for Now"}, {"id":141054556,"url":"https://finnhub.io/api/news?id=1d05afedea319df981c1c6f83addc02b5f0376cb79960f0906d78929147599c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.","category":"company","datetime":1785330300,"headline":"Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?"}, {"id":141044101,"url":"https://finnhub.io/api/news?id=c8653c2acc661d71ba770d3da529a4053e5cd75994323d7e47a99f7241814252","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.","category":"company","datetime":1785246180,"headline":"STERIS' Q1 Earnings on Deck: What's in Store for the Stock?"}, {"id":141033965,"url":"https://finnhub.io/api/news?id=5d7090a4fb695f255effb47da586d72dcf54b4a024ad6a80984d2819806eaa0c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MiniMed expands Flex access to Medicare beneficiaries, widening availability of its app-controlled pump and automated insulin delivery technology.","category":"company","datetime":1785158640,"headline":"MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care Access"}, {"id":141034163,"url":"https://finnhub.io/api/news?id=7dfbcbf4ac51d4c89fb1a320c9a619e05c9b4623934b10d1328c714f4f1f1c4e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.","category":"company","datetime":1785157860,"headline":"Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings"}, {"id":141032829,"url":"https://finnhub.io/api/news?id=e9669444eb7d54da770e3c0dfa28ef3a5858b6c67f0d7a5f6f15443a00e4cf3e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.","category":"company","datetime":1785154500,"headline":"Beat the Market Like Zacks: Monster Beverage, Carpenter Tech, Usio in Focus"}, {"id":141036813,"url":"https://finnhub.io/api/news?id=48d78e52e5d8f571f1bcb64a0c79f31b39f424296231eef82450cdb628989e75","image":"","source":"Benzinga","related":"WST","summary":"Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.","category":"company","datetime":1785149469,"headline":"Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425"}, {"id":141022425,"url":"https://finnhub.io/api/news?id=d1f78928e7480655f340713dfd950836c30c45378585800c56edff87a7b3ebc2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services (NYSE:WST) has entered new long-term exclusive and non-exclusive distributorship agreements with Daikyo Seiko. West Pharmaceutical will distribute Daikyo products outside Japan, while Daikyo will distribute more West products within Japan. The agreements are structured to run over the next decade, reinforcing the companies' cross-border partnership in drug packaging technologies. West Pharmaceutical Services comes into this new distribution arrangement with...","category":"company","datetime":1785042740,"headline":"West Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japan"}, {"id":141012217,"url":"https://finnhub.io/api/news?id=911ae89653143291a794bac10769990b0fa08687ccc7ab39b3d6261569feb355","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million","category":"company","datetime":1784933348,"headline":"Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know"}, {"id":141011008,"url":"https://finnhub.io/api/news?id=2b5681c8ad3445c10d7b6b93b6c6f3bb5e4d97717a3b68cc3433f7ac9b353349","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"Get the weekly dividend update for Champions, Contenders & Challengers—read about the dividend changes, upcoming ex-dividend dates and pay dates here.","category":"company","datetime":1784916411,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week Of July 26"}, {"id":141007082,"url":"https://finnhub.io/api/news?id=d659103d7d7b5ef979f73e9b619ecda56339bb5d1d3d2a3be050003d830e115a","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"WST","summary":"Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.","category":"company","datetime":1784910901,"headline":"Uncover the latest developments among S&P500 stocks in today's session."}, {"id":141007920,"url":"https://finnhub.io/api/news?id=87f8d85494584027365a3886769e86bfba2dbfdaab5bcc5ff6b64728ff179ba8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.","category":"company","datetime":1784905740,"headline":"Here's Why You Should Add Cencora Stock to Your Portfolio Now"}, {"id":141007921,"url":"https://finnhub.io/api/news?id=81d9e34fdfd7a95dd140c3b55594eacb4f418e518b7d324ee8d3ea4ef365f1e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.","category":"company","datetime":1784905500,"headline":"Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs"}, {"id":141006590,"url":"https://finnhub.io/api/news?id=b9d1dbac7b295758ca6240d77ce744fd68e68aaf1579f112a00365686f982e57","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.","category":"company","datetime":1784901600,"headline":"Here's Why You Should Hold Solventum Stock in Your Portfolio for Now"}, {"id":141005494,"url":"https://finnhub.io/api/news?id=7dcccb74b106c019d246e857f0bdac3ee97e6369aa115bcd9f80be7816496e1b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.","category":"company","datetime":1784899268,"headline":"WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook"}, {"id":141004552,"url":"https://finnhub.io/api/news?id=d23e098ae2c20882e87461faa9d40ca2c79f7c19fa20e35c11098ee1f230d26c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491276743/image_1491276743.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"West Pharmaceutical Services beats Q2 earnings, raises FY guidance, and sees biologics-driven margin gains. Click to read this earnings analysis of WST stock.","category":"company","datetime":1784880528,"headline":"West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift"}, {"id":141002334,"url":"https://finnhub.io/api/news?id=5e7f3ffcf3f03cc583f270f8c997b135e7a9dcd1cf65173f5c6354a4dd95a058","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C","category":"company","datetime":1784862272,"headline":"West Pharmaceutical Services Q2 Earnings Call Highlights"}, {"id":141002552,"url":"https://finnhub.io/api/news?id=487079e6b61eefd5cdfca70b26da7a475a464155c3130cda555b6479781c524b","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"WST","summary":"2026-07-24. The following slide deck was published by West Pharmaceutical Services, Inc.","category":"company","datetime":1784854848,"headline":"West Pharmaceutical Services, Inc. 2026 Q2 - Results - Earnings Call Presentation"}, {"id":140999440,"url":"https://finnhub.io/api/news?id=a3c1300db9b580986e56e96dd609fb6a0f382e04b69ba61818e02e24abd0cd48","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Moby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call","category":"company","datetime":1784840928,"headline":"West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary"}, {"id":140998038,"url":"https://finnhub.io/api/news?id=a83730c15d5e88f5dbcdc33d8d84d1765555e0ab8e4ef4e8e83560f359cab296","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.","category":"company","datetime":1784833298,"headline":"West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highlights: Strong Organic Growth ..."}, {"id":140997834,"url":"https://finnhub.io/api/news?id=8b5562ccad08c40b36749e0aaa7782b3c5636767b2c337583a15476bb8c73561","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.","category":"company","datetime":1784830080,"headline":"WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth"}, {"id":140997924,"url":"https://finnhub.io/api/news?id=c608774f8f6aaf6348c7b29c9bed00d94e9b347c5e5957dac96e10936ea0836d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.","category":"company","datetime":1784827980,"headline":"Reasons to Add QuidelOrtho Stock in Your Portfolio for Now"}, {"id":140997925,"url":"https://finnhub.io/api/news?id=6bec2c14e0d73dedc4197d0c596b947fcead06678116ed6826e141f2ca4addf9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.","category":"company","datetime":1784827620,"headline":"Smith+Nephew Expands ASC Platform to Support Value-Based Care"}, {"id":140997927,"url":"https://finnhub.io/api/news?id=68be10255c11549211d68a39b771f136b909b37f137f465234c6a8b5d1ac0697","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.","category":"company","datetime":1784823660,"headline":"Here's Why You Should Retain OPK Stock in Your Portfolio for Now"}, {"id":140997797,"url":"https://finnhub.io/api/news?id=3cbb38d923198032baed48e5d05dc6047f885315cb8b30cb7e2d44f8a571886d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.","category":"company","datetime":1784823060,"headline":"CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula"}, {"id":140995005,"url":"https://finnhub.io/api/news?id=0b66667a8b4ad924345baf0b6d2e2487f9122989012774013f8e77b7b7f09f5a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1784813407,"headline":"West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"}, {"id":140992858,"url":"https://finnhub.io/api/news?id=fc6e06457fb216266ed7ade2993afcedbedc6648f41f9685a003e7793ce61b00","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"WST","summary":"Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.","category":"company","datetime":1784810101,"headline":"These S&P500 stocks that are showing activity before the opening bell on Thursday."}, {"id":140993608,"url":"https://finnhub.io/api/news?id=d4e4688bf4dc2ee4d9238e59a8643a4c78970120d3d4d32033c44cc137c819d7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.","category":"company","datetime":1784807901,"headline":"West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars"}, {"id":140994444,"url":"https://finnhub.io/api/news?id=21604ef6b6313fd7f7d8bd6b312ff93f99af637b3548e8dba4c60285b5569317","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"WST","summary":"West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call July 23, 2026 8:00 AM EDTCompany ParticipantsJohn Sweeney - Vice President of Investor...","category":"company","datetime":1784806830,"headline":"West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcript"}, {"id":140994378,"url":"https://finnhub.io/api/news?id=e3a7ce5d82f7b847dbdf67897b280b68a1da3d34320d47d81285ae5103b86e72","image":"https://cdn.benzinga.com/files/images/story/2026/07/23/Hand-arranging-Wood-Block-With-Icon-Heal.jpg?width=2048&height=1536","source":"Benzinga","related":"WST","summary":"West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.","category":"company","datetime":1784806346,"headline":"West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum"}, {"id":140993539,"url":"https://finnhub.io/api/news?id=d04390a2f5d1a2ac12c0498d11018ae4d58fdbbed2027ac4d48b1ecb9c06efa1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical (WST) delivered earnings and revenue surprises of +13.94% and +4.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1784805304,"headline":"West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates"}, {"id":140992642,"url":"https://finnhub.io/api/news?id=812c6dd87d7a4f750682a61b3fab2d96f3371cda3b8f1d67c7eb0c77b20757ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share","category":"company","datetime":1784804052,"headline":"West Pharmaceutical Services Q2 Adjusted Earnings, Net Sales Rise; 2026 Outlook Boosted"}, {"id":140992643,"url":"https://finnhub.io/api/news?id=de92933d5d07aadf49e6290ac92f05a6bbf8433032b3f320c44f84699e37b1ed","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.","category":"company","datetime":1784800800,"headline":"West Reports Second-Quarter 2026 Results"}, {"id":140994379,"url":"https://finnhub.io/api/news?id=bfe6ab960e2f567243a916684c09e37fbb7d0afc5a37bf205759eadf4c762240","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536","source":"Benzinga","related":"WST","summary":"West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.\nBenzinga APIs provide real-time","category":"company","datetime":1784798574,"headline":"Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call"}, {"id":140993809,"url":"https://finnhub.io/api/news?id=a47ad7f0bc8a271af3493561d9e532c43ff1705e233807236e6b2cf91a6dc883","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536","source":"Benzinga","related":"WST","summary":"Companies Reporting Before The Bell\n• Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. \n• Dime Commercial (NYSE:DCOM) is expected to report","category":"company","datetime":1784790711,"headline":"Earnings Scheduled For July 23, 2026"}, {"id":140994381,"url":"https://finnhub.io/api/news?id=a437a6a837d4598cff87e81087d1ad59fc9a505ce89c1dd31aca78b7350f3566","image":"","source":"Benzinga","related":"WST","summary":"West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345 billion-$3.380","category":"company","datetime":1784786949,"headline":"West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est"}, {"id":140994382,"url":"https://finnhub.io/api/news?id=84ebed3f1bc7749097f271e9c1db21aa6a947e19e4b6393057c64785b8084b79","image":"","source":"Benzinga","related":"WST","summary":"West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..","category":"company","datetime":1784786908,"headline":"West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est"}, {"id":140994383,"url":"https://finnhub.io/api/news?id=94c45595e311a5a7d4074a554811853702f1b89c52ebe8f3c8aead621bee2935","image":"","source":"Benzinga","related":"WST","summary":"West Pharmaceutical Servs (NYSE:WST) is looking for Q3 Adj EPS of $2.14-$2.24 vs $2.12 analyst estimate. sees sales of $820.000 million-$835.000 million vs $815.707 million analyst estimate.","category":"company","datetime":1784786886,"headline":"West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est"}, {"id":140994384,"url":"https://finnhub.io/api/news?id=97986c99b8fe10a66f8e1579431e1d7674d878c22988c8103036bd4c88584816","image":"","source":"Benzinga","related":"WST","summary":"West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.08 by 13.94 percent. This is a 28.8 percent increase over earnings of $1.84 per share","category":"company","datetime":1784786875,"headline":"West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate"}, {"id":140984968,"url":"https://finnhub.io/api/news?id=cc24f23f73b8e9a4fbf38becde0290a14b386c510f656569e512a54b753432ef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect.","category":"company","datetime":1784737827,"headline":"West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For"}, {"id":140984919,"url":"https://finnhub.io/api/news?id=0441267e55f97ee798e15ff361d070bf1c8ed9dc01745bc7ba5ff30f934d5764","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"CAH is set to buy two home-care businesses for about $360 million, expanding diabetes and urology reach while targeting first-year EPS accretion.","category":"company","datetime":1784737140,"headline":"Cardinal Health Expands Home Care Business With Two Acquisitions"}, {"id":140984920,"url":"https://finnhub.io/api/news?id=baf18e37cd128514c37b8ec0c38c1918eac8f805b29c5b540d025957786c2803","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.","category":"company","datetime":1784732640,"headline":"Revvity to Launch Signals for Startups for Emerging Biotech Companies"}, {"id":140978882,"url":"https://finnhub.io/api/news?id=4757c19fd5969527f9d29b3ed3b233d35b094fd4f2882a21a324b468cd87c0a3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services stock has delivered a 64.7% return over the past year, yet the valuation checks and current pricing suggest it may no longer be an obvious bargain, with the Discounted Cash Flow (DCF) estimate pointing to a level that is roughly in line with where the shares trade today. After such a strong run, investors are weighing solid business developments against signals that the stock screens as expensive on several measures. Over the past 1 year, West Pharmaceutical...","category":"company","datetime":1784686321,"headline":"West (WST) Stock Looks Pricey With Little Room Above Fair Value"}, {"id":140976533,"url":"https://finnhub.io/api/news?id=28aecd823d339afb471ca9026f1ca8d33d516ebbaeab490559e50e4ff1c45a6e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026.","category":"company","datetime":1784664000,"headline":"West Declares Quarterly Dividend"}, {"id":140973539,"url":"https://finnhub.io/api/news?id=fc59b28a72e9fb67c5de58ff9b6deef6c4e9908ebb0d5136f53ed8bdb8d7d728","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.","category":"company","datetime":1784647920,"headline":"WST Likely to Beat Q2 Earnings Estimates: How to Play the Stock?"}, {"id":140973584,"url":"https://finnhub.io/api/news?id=16836b16b30266ddee8f327aa9d7b895752a5d1fd7496fd5c676215fdc6e4ee3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.","category":"company","datetime":1784647860,"headline":"Omnicell to Report Q2 Earnings: OmniSphere in Focus"}, {"id":140971931,"url":"https://finnhub.io/api/news?id=893e8bb7b41a606d4a508201130b3480b11bfd298966a40792889fd1dd974627","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"GE HealthCare's MIM Anyware offers secure browser-based imaging access to streamline workflows, collaboration and clinical decision-making.","category":"company","datetime":1784645280,"headline":"GEHC Launches MIM Anyware for Secure Remote Imaging Collaboration"}, {"id":140971621,"url":"https://finnhub.io/api/news?id=ecc1da10ef106529290939101533f8a9832eadb8bd45283aaf71baea5eb03546","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Wall Street closed lower on Monday, pulled down by healthcare and industrial stocks.","category":"company","datetime":1784640360,"headline":"Stock Market News for July 21, 2026"}, {"id":140971999,"url":"https://finnhub.io/api/news?id=332614d04f934331b6fc86cdc065aae05629a2376bc4c6ae936078201a21fc45","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Besides Wall Street's top-and-bottom-line estimates for West Pharmaceutical (WST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.","category":"company","datetime":1784639708,"headline":"Curious about West Pharmaceutical (WST) Q2 Performance? Explore Wall Street Estimates for Key Metrics"}, {"id":140962292,"url":"https://finnhub.io/api/news?id=d24c4fe2b5991843e4a8f72514f648c4b4214b09dcdb126e31ec51daa60783bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MMSI vs. WST: Which Stock Is the Better Value Option?","category":"company","datetime":1784562005,"headline":"MMSI vs. WST: Which Stock Should Value Investors Buy Now?"}, {"id":140961057,"url":"https://finnhub.io/api/news?id=7b57cd626dbf5494bbcf5873b3e42358e0db50e5d14043ee30cf4dd6a6200c55","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.","category":"company","datetime":1784558520,"headline":"Align Technology to Report Q2 Earnings: Clear Aligner Segment in Focus"}, {"id":140960847,"url":"https://finnhub.io/api/news?id=81a8003193de79a3dbfb4e8aa9044d29e2a2203770ac8a44b4e0a51c3b594d32","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.","category":"company","datetime":1784555640,"headline":"Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S."}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 5
recomputed_at_score true
sentiment_score_raw 1.5
source_article_count 93
discarded_article_count 71
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.2 5/110 64% 3.2
資金流 10.8 20/110 54% 10.8
市場環境 12.2 15/110 81.33% 12.2
催化劑 6 20/110 30% 6
風險管理 7.4 10/110 74% 7.4
技術信號 17.3 30/110 57.67% 17.3
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 3/50
ret_5d -0.0136
max_score 50
max_total 50
raw_total 3
vcp_bonus 0
vol_ratio 0.2461
ret_points 0
vol_points 0
range_ratio 0.4315
volat_points 0
day_range_pct 0.0121
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 1.9063
turnoverUsdM 65.5887
liquidityPoints 0.4
volatilityPoints 1.2
rrPoints 1.4

stopLevels

symbol US.WST
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 333.3758

strength_details

ma_score 1
atr_score 2.5
rsi_score 3
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.3
stop_loss_percent 3.8
take_profit_price 363.9195
target_multiplier 1.9
technical_strength 1.75
take_profit_percent 5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.3114
stopLossPercent 3.8126
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.2/5分
資金流分析總分: 10.8/20分
市場環境分析總分: 12.2/15分
催化劑分析: 6/20分
風險管理總分: 7.4/10分
技術信號分析總分: 17.3/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 6.6071
rule ATR / current price; lower volatility scores higher
score 8
atr_pct 1.91
cci
rule Cursor_18.24 CCI bands
level 平衡
score 6
value 2.23
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.0989
kdj
d 46.48
j 9.01
k 33.99
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 入貨中
score 8
value 69.05
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 4
trend 弱勢
value 7762460
recentSlope -136964
previousSlope 333300
rsi
value 62.24
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 344.5397
position SAR喺價下
distancePct 0.59
previousTrend 上升
ma50
value 346.321
macd
macd 0.5856
trend 中性偏多
signal 0.9183
histogram -0.3328
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 8
value 345.7676
position 連續3日>VWAP
consecutiveAbove 3
volume
rule Cursor_18.24 volume ratio
level 空升
ratio 0.26
score 2
avgVolume 740917
currentVolume 189240
derived
ma20 346.1655
ma50 346.321
prevClose 346.61
avgVolume10 450984
avgVolume20 740917
changePercent -0.01
avgVolumeForScore 740917
ma_cross
ma20 346.1655
ma50 346.321
rule Cursor_18.24 MA20/MA50 cross
cross 下穿
score 2
prevMa20 346.798
prevMa50 345.6792
spreadPct 0.04
isVolumeBreakout false
bollinger
lower 330.5128
upper 361.8182
position 上半部
rsi_short
value 30.07
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.26

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 1.9063158198447734,
        "turnoverUsdM": 65.58869159999999,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.WST",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 333.3758,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2.5,
        "rsi_score": 3,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.8,
      "take_profit_price": 363.9195,
      "target_multiplier": 1.9,
      "technical_strength": 1.75,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.3114301281954261,
    "stopLossPercent": 3.8126316396895468,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 62.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 346.1655,
    "ma50": 346.321,
    "close": 346.59,
    "prevClose": 346.61,
    "avgVolume20": 740917,
    "volumeRatio": 0.26,
    "changePercent": -0.01
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.013603893331815553,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.24605702843620383,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.43153287959254755,
      "volat_points": 0,
      "day_range_pct": 0.012146894024640064,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 12.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 81.33,
        "contribution": 12.2
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 17.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 57.67,
        "contribution": 17.3
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 62.9,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 12.2/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 17.3/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 3.2,
      "資金流": 10.8,
      "市場環境": 12.2,
      "情緒分析": 6,
      "技術信號": 17.3,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.6,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 65.58869159999999,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 1.6,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.WST",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "優秀",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.19
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 706.2430000000002,
                "ma50": 712.98440224,
                "name": "QQQ",
                "close": 717.51001,
                "points": 1.4
              },
              "spy": {
                "ma20": 758.6840022499998,
                "ma50": 749.8360044,
                "name": "SPY",
                "close": 767.45001,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9063158198447734,
          "atrPoints": 4,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 5,
              "sentimentScoreRaw": 1.5
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              },
              {
                "id": 141209368,
                "url": "https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"
              },
              {
                "id": 141202470,
                "url": "https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...",
                "category": "company",
                "datetime": 1786518635,
                "headline": "West (WST) Stock Looks Overvalued After A 47% One Year Run"
              },
              {
                "id": 141135724,
                "url": "https://finnhub.io/api/news?id=8e4664598d306ae1ef59232b19e85e05ac357109829847b04453f423292922d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]",
                "category": "company",
                "datetime": 1786024529,
                "headline": "Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2"
              },
              {
                "id": 141105188,
                "url": "https://finnhub.io/api/news?id=8445c0043c52e4322380ebeeeaf25c5b1f27d7b1521d55b5c046a500753c77ad",
                "image": "",
                "source": "Fintel",
                "related": "WST",
                "summary": "",
                "category": "company",
                "datetime": 1785810547,
                "headline": "West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03"
              },
              {
                "id": 141097112,
                "url": "https://finnhub.io/api/news?id=ed7760005858daa2fb47089e589aba505882a88fd96abb4b0157752c40e9e312",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...",
                "category": "company",
                "datetime": 1785733722,
                "headline": "Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?"
              },
              {
                "id": 141097113,
                "url": "https://finnhub.io/api/news?id=3672b37da6f185069441e06aab66c46e1ec0c85928bdd57eb6c303fe26995654",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services (WST) has drawn fresh investor attention after reporting second quarter results that exceeded expectations and raising full year revenue and adjusted earnings guidance, supported by demand for biologics and biosimilars related products. See our latest analysis for West Pharmaceutical Services. The share price has been volatile in recent months, with a 13.4% 90 day share price return and 23.4% year to date share price return, but a 6.6% decline over 30 days as...",
                "category": "company",
                "datetime": 1785731538,
                "headline": "West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?"
              }
            ],
            "raw_source": [
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              },
              {
                "id": 141209368,
                "url": "https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"
              },
              {
                "id": 141202468,
                "url": "https://finnhub.io/api/news?id=d0e7e846d43e052f5cf2cc75222b2e19cdf44371cf038926785d5e1b34db15a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.",
                "category": "company",
                "datetime": 1786549260,
                "headline": "Here's Why You Should Add BrightSpring Stock to Your Portfolio Now"
              },
              {
                "id": 141202469,
                "url": "https://finnhub.io/api/news?id=e0277f3fb832d7629b5cfa40809a7c12d4b0dd92ab901d8e20bba9889d3940ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.",
                "category": "company",
                "datetime": 1786548120,
                "headline": "NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up"
              },
              {
                "id": 141202470,
                "url": "https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...",
                "category": "company",
                "datetime": 1786518635,
                "headline": "West (WST) Stock Looks Overvalued After A 47% One Year Run"
              },
              {
                "id": 141202034,
                "url": "https://finnhub.io/api/news?id=c70632c2f9259acf971a4ff2e21f3a79f70231e7041cbbc36844dbb90356e0cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.",
                "category": "company",
                "datetime": 1786465260,
                "headline": "CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up"
              },
              {
                "id": 141202035,
                "url": "https://finnhub.io/api/news?id=5b2009080943f484ca312cf2ddae85582953343181666e7127ac9f3833e34b70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.",
                "category": "company",
                "datetime": 1786461600,
                "headline": "RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised"
              },
              {
                "id": 141177784,
                "url": "https://finnhub.io/api/news?id=2b214d626c55d69f3321fcb009f6866c20e2d848f4d640c809751929b9c57eb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1786380840,
                "headline": "Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut"
              },
              {
                "id": 141176776,
                "url": "https://finnhub.io/api/news?id=51215d10973a1d3873da231aeeefd48c6bc09a21e18da33bfd7c86363e77526d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.",
                "category": "company",
                "datetime": 1786379820,
                "headline": "iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised"
              },
              {
                "id": 141164828,
                "url": "https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.",
                "category": "company",
                "datetime": 1786243803,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For August 2026"
              },
              {
                "id": 141153743,
                "url": "https://finnhub.io/api/news?id=480497e730b8ea5e3d057667533cf1edc2347a0cb1c86eb68ed0787f76b9527b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Management put a much higher number on its future, and the stock has been on a tear ever since. But is this a fleeting AI boom or a fundamental rewiring of the business.",
                "category": "company",
                "datetime": 1786139750,
                "headline": "Cisco Stock Is Finally Pricing In A New Growth Story"
              },
              {
                "id": 141151192,
                "url": "https://finnhub.io/api/news?id=fc7d6e4a19b1ecefa500bbfc8e2e25de6b5c94dd43bc59e1620796a4007a8a89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.",
                "category": "company",
                "datetime": 1786127700,
                "headline": "XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales"
              },
              {
                "id": 141149609,
                "url": "https://finnhub.io/api/news?id=328e13ad11d15da6764538592fc4d871018f1a757eb98788f0e82e7cddc1f178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.",
                "category": "company",
                "datetime": 1786121220,
                "headline": "AMN Q2 Earnings Beat Estimates on Staffing and Search Growth, Stock Up"
              },
              {
                "id": 141149610,
                "url": "https://finnhub.io/api/news?id=8e5bd7fa2a58cd02c146fd34fccaed30767229053dcd7376a68126d672047d2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.",
                "category": "company",
                "datetime": 1786120560,
                "headline": "DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up"
              },
              {
                "id": 141140628,
                "url": "https://finnhub.io/api/news?id=a8b9dcae545cc5c62870f85c5a89bc5758dc075833203dde38abaea6245b92f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.",
                "category": "company",
                "datetime": 1786035840,
                "headline": "PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut"
              },
              {
                "id": 141137316,
                "url": "https://finnhub.io/api/news?id=f23c7f57565c87589923985dcfb23a36115479fe932f711cc0df05b80818daf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.",
                "category": "company",
                "datetime": 1786033860,
                "headline": "LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised"
              },
              {
                "id": 141137317,
                "url": "https://finnhub.io/api/news?id=800e586663a06c21846fb4704cde171e522540f493e9141574d3def76d3d7334",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.",
                "category": "company",
                "datetime": 1786030860,
                "headline": "MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised"
              },
              {
                "id": 141135724,
                "url": "https://finnhub.io/api/news?id=8e4664598d306ae1ef59232b19e85e05ac357109829847b04453f423292922d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]",
                "category": "company",
                "datetime": 1786024529,
                "headline": "Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2"
              },
              {
                "id": 141125909,
                "url": "https://finnhub.io/api/news?id=4cc57192c03dfc0eedad44bf9d950f4c8edb9fb26d63e7e6f813fcb1fdc036e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.",
                "category": "company",
                "datetime": 1785952920,
                "headline": "Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?"
              },
              {
                "id": 141124354,
                "url": "https://finnhub.io/api/news?id=3c99f0ca4df1360198bfda8776337250d51ac456a32bc832bac0b78ca6f14858",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Hinge Health's Q2 revenues jump 53% as stronger member yield, margin gains and raised 2026 guidance reinforce business momentum.",
                "category": "company",
                "datetime": 1785948000,
                "headline": "HNGE Q2 Earnings Meet Estimates, Sales Top, '26 View Raised, Stock Up"
              },
              {
                "id": 141122656,
                "url": "https://finnhub.io/api/news?id=026d8fb37247e734556ab139d7617d44722f4e154e1c54607e4041ad152a13a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.",
                "category": "company",
                "datetime": 1785941400,
                "headline": "COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised"
              },
              {
                "id": 141122657,
                "url": "https://finnhub.io/api/news?id=d65126c035551814d108e50a1313d81a1237d5b5ba6733964cc3b8dad767605a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.",
                "category": "company",
                "datetime": 1785941340,
                "headline": "FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand"
              },
              {
                "id": 141114964,
                "url": "https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.",
                "category": "company",
                "datetime": 1785870540,
                "headline": "RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"
              },
              {
                "id": 141112034,
                "url": "https://finnhub.io/api/news?id=29220b2023579682d098f84e1a9bd930eeb6b970fa72c6152de3c809aefed06f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.",
                "category": "company",
                "datetime": 1785862680,
                "headline": "Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up"
              },
              {
                "id": 141105188,
                "url": "https://finnhub.io/api/news?id=8445c0043c52e4322380ebeeeaf25c5b1f27d7b1521d55b5c046a500753c77ad",
                "image": "",
                "source": "Fintel",
                "related": "WST",
                "summary": "",
                "category": "company",
                "datetime": 1785810547,
                "headline": "West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03"
              },
              {
                "id": 141102471,
                "url": "https://finnhub.io/api/news?id=30596f6493c7617c08324dee7f0bc7938ac6cda5b78e1147447672994f261dbc",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.",
                "category": "company",
                "datetime": 1785768764,
                "headline": "Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412"
              },
              {
                "id": 141097112,
                "url": "https://finnhub.io/api/news?id=ed7760005858daa2fb47089e589aba505882a88fd96abb4b0157752c40e9e312",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...",
                "category": "company",
                "datetime": 1785733722,
                "headline": "Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?"
              },
              {
                "id": 141097113,
                "url": "https://finnhub.io/api/news?id=3672b37da6f185069441e06aab66c46e1ec0c85928bdd57eb6c303fe26995654",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services (WST) has drawn fresh investor attention after reporting second quarter results that exceeded expectations and raising full year revenue and adjusted earnings guidance, supported by demand for biologics and biosimilars related products. See our latest analysis for West Pharmaceutical Services. The share price has been volatile in recent months, with a 13.4% 90 day share price return and 23.4% year to date share price return, but a 6.6% decline over 30 days as...",
                "category": "company",
                "datetime": 1785731538,
                "headline": "West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?"
              },
              {
                "id": 141087819,
                "url": "https://finnhub.io/api/news?id=440ad6f9856caed08f8f38e51aff99b0e745775dcc353978de6ea663dfb2602f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the compan",
                "category": "company",
                "datetime": 1785596397,
                "headline": "The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call"
              },
              {
                "id": 141086424,
                "url": "https://finnhub.io/api/news?id=3a243f9a49b7b9f0ce5ee608668ded9b9c22573de813e7bfe8c1d840a90af833",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1785575757,
                "headline": "3 Reasons to Avoid WST and 1 Stock to Buy Instead"
              },
              {
                "id": 141084159,
                "url": "https://finnhub.io/api/news?id=b01254886ca04bb4ee2ca13216638f12f5b9bc0c9bbe991af37b4d7b45adc14c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read now.",
                "category": "company",
                "datetime": 1785532692,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 2"
              },
              {
                "id": 141080482,
                "url": "https://finnhub.io/api/news?id=3b0428d64cc3da400032a5c5321ae5b4192319def2ec16d669798ecea40d5a20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
                "category": "company",
                "datetime": 1785516717,
                "headline": "3 Cash-Heavy Stocks We Approach with Caution"
              },
              {
                "id": 141080381,
                "url": "https://finnhub.io/api/news?id=c1245c5746c22ff46ef9ac1ca560e75935767219c3b020b02059cac810c7e881",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.",
                "category": "company",
                "datetime": 1785510480,
                "headline": "MMSI Q2 Earnings & Revenues Beat Estimates, '26 Guidance Raised"
              },
              {
                "id": 141079192,
                "url": "https://finnhub.io/api/news?id=ba7731a4b95a73e9b539fb9155adffe31e1dea22943a4c45be8f8fa12e57990b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.",
                "category": "company",
                "datetime": 1785504720,
                "headline": "Resmed's Q4 Earnings on Deck: What's in Store for the Stock?"
              },
              {
                "id": 141079102,
                "url": "https://finnhub.io/api/news?id=693d7da201dd6ee1737f170709fd5edad838d6fb56b43a75a77dcfa9ba5d0007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.",
                "category": "company",
                "datetime": 1785504660,
                "headline": "SYK Falls Despite Q2 Earnings Beat on Strong Sales and Cyber Recovery"
              },
              {
                "id": 141077645,
                "url": "https://finnhub.io/api/news?id=5714fc9c6779de656a4e2a6b8b9d2ce3f672f1d8914a60d2ed397cf1fb5e57a1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205618145/image_2205618145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.",
                "category": "company",
                "datetime": 1785487080,
                "headline": "Conestoga SMid Cap Composite Q2 2026 Portfolio Review"
              },
              {
                "id": 141068411,
                "url": "https://finnhub.io/api/news?id=0007ffe0216e700b6c8ed0b3e1049e7206b7730a714da3b4daae9f8b75ec010f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.",
                "category": "company",
                "datetime": 1785427320,
                "headline": "BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract"
              },
              {
                "id": 141068412,
                "url": "https://finnhub.io/api/news?id=cc292e3b8f12ff007275fcb1af654d34bc6fe0a8a71b1d867b4bfd95cdd330fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.",
                "category": "company",
                "datetime": 1785426900,
                "headline": "Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up"
              },
              {
                "id": 141059588,
                "url": "https://finnhub.io/api/news?id=67311e2187c8daa5f97909344e3c76b99fbde905a77e989bccdfea2563d55757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225310528/image_2225310528.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "NOBL beats SPY YTD in 2026; explore 25 undervalued Dividend Aristocrats with 10%+ projected returns and fresh dividend hikes—see the list now.",
                "category": "company",
                "datetime": 1785354040,
                "headline": "Best Dividend Aristocrats For August 2026"
              },
              {
                "id": 141055862,
                "url": "https://finnhub.io/api/news?id=d2c593c9349957b3ca16152323c967c4417d3ab3f9db8797978f488a55bb6f6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.",
                "category": "company",
                "datetime": 1785339720,
                "headline": "GEHC Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market"
              },
              {
                "id": 141055863,
                "url": "https://finnhub.io/api/news?id=dc6b208f3d8cb61b19b3c297a8cc56c2951996a4af7af738c66e92cd98982229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.",
                "category": "company",
                "datetime": 1785337380,
                "headline": "Here's Why You Should Retain DaVita Stock in Your Portfolio for Now"
              },
              {
                "id": 141054556,
                "url": "https://finnhub.io/api/news?id=1d05afedea319df981c1c6f83addc02b5f0376cb79960f0906d78929147599c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.",
                "category": "company",
                "datetime": 1785330300,
                "headline": "Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?"
              },
              {
                "id": 141044101,
                "url": "https://finnhub.io/api/news?id=c8653c2acc661d71ba770d3da529a4053e5cd75994323d7e47a99f7241814252",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.",
                "category": "company",
                "datetime": 1785246180,
                "headline": "STERIS' Q1 Earnings on Deck: What's in Store for the Stock?"
              },
              {
                "id": 141033965,
                "url": "https://finnhub.io/api/news?id=5d7090a4fb695f255effb47da586d72dcf54b4a024ad6a80984d2819806eaa0c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MiniMed expands Flex access to Medicare beneficiaries, widening availability of its app-controlled pump and automated insulin delivery technology.",
                "category": "company",
                "datetime": 1785158640,
                "headline": "MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care Access"
              },
              {
                "id": 141034163,
                "url": "https://finnhub.io/api/news?id=7dfbcbf4ac51d4c89fb1a320c9a619e05c9b4623934b10d1328c714f4f1f1c4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.",
                "category": "company",
                "datetime": 1785157860,
                "headline": "Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings"
              },
              {
                "id": 141032829,
                "url": "https://finnhub.io/api/news?id=e9669444eb7d54da770e3c0dfa28ef3a5858b6c67f0d7a5f6f15443a00e4cf3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.",
                "category": "company",
                "datetime": 1785154500,
                "headline": "Beat the Market Like Zacks: Monster Beverage, Carpenter Tech, Usio in Focus"
              },
              {
                "id": 141036813,
                "url": "https://finnhub.io/api/news?id=48d78e52e5d8f571f1bcb64a0c79f31b39f424296231eef82450cdb628989e75",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "Evercore ISI Group  analyst Daniel Markowitz   maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.",
                "category": "company",
                "datetime": 1785149469,
                "headline": "Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425"
              },
              {
                "id": 141022425,
                "url": "https://finnhub.io/api/news?id=d1f78928e7480655f340713dfd950836c30c45378585800c56edff87a7b3ebc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services (NYSE:WST) has entered new long-term exclusive and non-exclusive distributorship agreements with Daikyo Seiko. West Pharmaceutical will distribute Daikyo products outside Japan, while Daikyo will distribute more West products within Japan. The agreements are structured to run over the next decade, reinforcing the companies' cross-border partnership in drug packaging technologies. West Pharmaceutical Services comes into this new distribution arrangement with...",
                "category": "company",
                "datetime": 1785042740,
                "headline": "West Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japan"
              },
              {
                "id": 141012217,
                "url": "https://finnhub.io/api/news?id=911ae89653143291a794bac10769990b0fa08687ccc7ab39b3d6261569feb355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million",
                "category": "company",
                "datetime": 1784933348,
                "headline": "Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know"
              },
              {
                "id": 141011008,
                "url": "https://finnhub.io/api/news?id=2b5681c8ad3445c10d7b6b93b6c6f3bb5e4d97717a3b68cc3433f7ac9b353349",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "Get the weekly dividend update for Champions, Contenders & Challengers—read about the dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1784916411,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 26"
              },
              {
                "id": 141007082,
                "url": "https://finnhub.io/api/news?id=d659103d7d7b5ef979f73e9b619ecda56339bb5d1d3d2a3be050003d830e115a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "WST",
                "summary": "Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1784910901,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 141007920,
                "url": "https://finnhub.io/api/news?id=87f8d85494584027365a3886769e86bfba2dbfdaab5bcc5ff6b64728ff179ba8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.",
                "category": "company",
                "datetime": 1784905740,
                "headline": "Here's Why You Should Add Cencora Stock to Your Portfolio Now"
              },
              {
                "id": 141007921,
                "url": "https://finnhub.io/api/news?id=81d9e34fdfd7a95dd140c3b55594eacb4f418e518b7d324ee8d3ea4ef365f1e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.",
                "category": "company",
                "datetime": 1784905500,
                "headline": "Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs"
              },
              {
                "id": 141006590,
                "url": "https://finnhub.io/api/news?id=b9d1dbac7b295758ca6240d77ce744fd68e68aaf1579f112a00365686f982e57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.",
                "category": "company",
                "datetime": 1784901600,
                "headline": "Here's Why You Should Hold Solventum Stock in Your Portfolio for Now"
              },
              {
                "id": 141005494,
                "url": "https://finnhub.io/api/news?id=7dcccb74b106c019d246e857f0bdac3ee97e6369aa115bcd9f80be7816496e1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1784899268,
                "headline": "WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook"
              },
              {
                "id": 141004552,
                "url": "https://finnhub.io/api/news?id=d23e098ae2c20882e87461faa9d40ca2c79f7c19fa20e35c11098ee1f230d26c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491276743/image_1491276743.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "West Pharmaceutical Services beats Q2 earnings, raises FY guidance, and sees biologics-driven margin gains. Click to read this earnings analysis of WST stock.",
                "category": "company",
                "datetime": 1784880528,
                "headline": "West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift"
              },
              {
                "id": 141002334,
                "url": "https://finnhub.io/api/news?id=5e7f3ffcf3f03cc583f270f8c997b135e7a9dcd1cf65173f5c6354a4dd95a058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C",
                "category": "company",
                "datetime": 1784862272,
                "headline": "West Pharmaceutical Services Q2 Earnings Call Highlights"
              },
              {
                "id": 141002552,
                "url": "https://finnhub.io/api/news?id=487079e6b61eefd5cdfca70b26da7a475a464155c3130cda555b6479781c524b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "2026-07-24. The following slide deck was published by West Pharmaceutical Services, Inc.",
                "category": "company",
                "datetime": 1784854848,
                "headline": "West Pharmaceutical Services, Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 140999440,
                "url": "https://finnhub.io/api/news?id=a3c1300db9b580986e56e96dd609fb6a0f382e04b69ba61818e02e24abd0cd48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Moby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1784840928,
                "headline": "West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 140998038,
                "url": "https://finnhub.io/api/news?id=a83730c15d5e88f5dbcdc33d8d84d1765555e0ab8e4ef4e8e83560f359cab296",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.",
                "category": "company",
                "datetime": 1784833298,
                "headline": "West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highlights: Strong Organic Growth ..."
              },
              {
                "id": 140997834,
                "url": "https://finnhub.io/api/news?id=8b5562ccad08c40b36749e0aaa7782b3c5636767b2c337583a15476bb8c73561",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.",
                "category": "company",
                "datetime": 1784830080,
                "headline": "WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth"
              },
              {
                "id": 140997924,
                "url": "https://finnhub.io/api/news?id=c608774f8f6aaf6348c7b29c9bed00d94e9b347c5e5957dac96e10936ea0836d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.",
                "category": "company",
                "datetime": 1784827980,
                "headline": "Reasons to Add QuidelOrtho Stock in Your Portfolio for Now"
              },
              {
                "id": 140997925,
                "url": "https://finnhub.io/api/news?id=6bec2c14e0d73dedc4197d0c596b947fcead06678116ed6826e141f2ca4addf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.",
                "category": "company",
                "datetime": 1784827620,
                "headline": "Smith+Nephew Expands ASC Platform to Support Value-Based Care"
              },
              {
                "id": 140997927,
                "url": "https://finnhub.io/api/news?id=68be10255c11549211d68a39b771f136b909b37f137f465234c6a8b5d1ac0697",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.",
                "category": "company",
                "datetime": 1784823660,
                "headline": "Here's Why You Should Retain OPK Stock in Your Portfolio for Now"
              },
              {
                "id": 140997797,
                "url": "https://finnhub.io/api/news?id=3cbb38d923198032baed48e5d05dc6047f885315cb8b30cb7e2d44f8a571886d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.",
                "category": "company",
                "datetime": 1784823060,
                "headline": "CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula"
              },
              {
                "id": 140995005,
                "url": "https://finnhub.io/api/news?id=0b66667a8b4ad924345baf0b6d2e2487f9122989012774013f8e77b7b7f09f5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1784813407,
                "headline": "West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 140992858,
                "url": "https://finnhub.io/api/news?id=fc6e06457fb216266ed7ade2993afcedbedc6648f41f9685a003e7793ce61b00",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "WST",
                "summary": "Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.",
                "category": "company",
                "datetime": 1784810101,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Thursday."
              },
              {
                "id": 140993608,
                "url": "https://finnhub.io/api/news?id=d4e4688bf4dc2ee4d9238e59a8643a4c78970120d3d4d32033c44cc137c819d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1784807901,
                "headline": "West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars"
              },
              {
                "id": 140994444,
                "url": "https://finnhub.io/api/news?id=21604ef6b6313fd7f7d8bd6b312ff93f99af637b3548e8dba4c60285b5569317",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call July 23, 2026 8:00 AM EDTCompany ParticipantsJohn Sweeney - Vice President of Investor...",
                "category": "company",
                "datetime": 1784806830,
                "headline": "West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140994378,
                "url": "https://finnhub.io/api/news?id=e3a7ce5d82f7b847dbdf67897b280b68a1da3d34320d47d81285ae5103b86e72",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Hand-arranging-Wood-Block-With-Icon-Heal.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "WST",
                "summary": "West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.",
                "category": "company",
                "datetime": 1784806346,
                "headline": "West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum"
              },
              {
                "id": 140993539,
                "url": "https://finnhub.io/api/news?id=d04390a2f5d1a2ac12c0498d11018ae4d58fdbbed2027ac4d48b1ecb9c06efa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical (WST) delivered earnings and revenue surprises of +13.94% and +4.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784805304,
                "headline": "West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 140992642,
                "url": "https://finnhub.io/api/news?id=812c6dd87d7a4f750682a61b3fab2d96f3371cda3b8f1d67c7eb0c77b20757ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share",
                "category": "company",
                "datetime": 1784804052,
                "headline": "West Pharmaceutical Services Q2 Adjusted Earnings, Net Sales Rise; 2026 Outlook Boosted"
              },
              {
                "id": 140992643,
                "url": "https://finnhub.io/api/news?id=de92933d5d07aadf49e6290ac92f05a6bbf8433032b3f320c44f84699e37b1ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.",
                "category": "company",
                "datetime": 1784800800,
                "headline": "West Reports Second-Quarter 2026 Results"
              },
              {
                "id": 140994379,
                "url": "https://finnhub.io/api/news?id=bfe6ab960e2f567243a916684c09e37fbb7d0afc5a37bf205759eadf4c762240",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "WST",
                "summary": "West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.\nBenzinga APIs provide real-time",
                "category": "company",
                "datetime": 1784798574,
                "headline": "Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call"
              },
              {
                "id": 140993809,
                "url": "https://finnhub.io/api/news?id=a47ad7f0bc8a271af3493561d9e532c43ff1705e233807236e6b2cf91a6dc883",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "WST",
                "summary": "Companies Reporting Before The Bell\n• Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. \n• Dime Commercial (NYSE:DCOM) is expected to report",
                "category": "company",
                "datetime": 1784790711,
                "headline": "Earnings Scheduled For July 23, 2026"
              },
              {
                "id": 140994381,
                "url": "https://finnhub.io/api/news?id=a437a6a837d4598cff87e81087d1ad59fc9a505ce89c1dd31aca78b7350f3566",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345 billion-$3.380",
                "category": "company",
                "datetime": 1784786949,
                "headline": "West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est"
              },
              {
                "id": 140994382,
                "url": "https://finnhub.io/api/news?id=84ebed3f1bc7749097f271e9c1db21aa6a947e19e4b6393057c64785b8084b79",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..",
                "category": "company",
                "datetime": 1784786908,
                "headline": "West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est"
              },
              {
                "id": 140994383,
                "url": "https://finnhub.io/api/news?id=94c45595e311a5a7d4074a554811853702f1b89c52ebe8f3c8aead621bee2935",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "West Pharmaceutical Servs (NYSE:WST) is looking for Q3 Adj EPS of $2.14-$2.24 vs $2.12 analyst estimate. sees sales of $820.000 million-$835.000 million vs $815.707 million analyst estimate.",
                "category": "company",
                "datetime": 1784786886,
                "headline": "West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est"
              },
              {
                "id": 140994384,
                "url": "https://finnhub.io/api/news?id=97986c99b8fe10a66f8e1579431e1d7674d878c22988c8103036bd4c88584816",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.08 by 13.94 percent. This is a 28.8 percent increase over earnings of $1.84 per share",
                "category": "company",
                "datetime": 1784786875,
                "headline": "West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate"
              },
              {
                "id": 140984968,
                "url": "https://finnhub.io/api/news?id=cc24f23f73b8e9a4fbf38becde0290a14b386c510f656569e512a54b753432ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect.",
                "category": "company",
                "datetime": 1784737827,
                "headline": "West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For"
              },
              {
                "id": 140984919,
                "url": "https://finnhub.io/api/news?id=0441267e55f97ee798e15ff361d070bf1c8ed9dc01745bc7ba5ff30f934d5764",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CAH is set to buy two home-care businesses for about $360 million, expanding diabetes and urology reach while targeting first-year EPS accretion.",
                "category": "company",
                "datetime": 1784737140,
                "headline": "Cardinal Health Expands Home Care Business With Two Acquisitions"
              },
              {
                "id": 140984920,
                "url": "https://finnhub.io/api/news?id=baf18e37cd128514c37b8ec0c38c1918eac8f805b29c5b540d025957786c2803",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.",
                "category": "company",
                "datetime": 1784732640,
                "headline": "Revvity to Launch Signals for Startups for Emerging Biotech Companies"
              },
              {
                "id": 140978882,
                "url": "https://finnhub.io/api/news?id=4757c19fd5969527f9d29b3ed3b233d35b094fd4f2882a21a324b468cd87c0a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services stock has delivered a 64.7% return over the past year, yet the valuation checks and current pricing suggest it may no longer be an obvious bargain, with the Discounted Cash Flow (DCF) estimate pointing to a level that is roughly in line with where the shares trade today. After such a strong run, investors are weighing solid business developments against signals that the stock screens as expensive on several measures. Over the past 1 year, West Pharmaceutical...",
                "category": "company",
                "datetime": 1784686321,
                "headline": "West (WST) Stock Looks Pricey With Little Room Above Fair Value"
              },
              {
                "id": 140976533,
                "url": "https://finnhub.io/api/news?id=28aecd823d339afb471ca9026f1ca8d33d516ebbaeab490559e50e4ff1c45a6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026.",
                "category": "company",
                "datetime": 1784664000,
                "headline": "West Declares Quarterly Dividend"
              },
              {
                "id": 140973539,
                "url": "https://finnhub.io/api/news?id=fc59b28a72e9fb67c5de58ff9b6deef6c4e9908ebb0d5136f53ed8bdb8d7d728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.",
                "category": "company",
                "datetime": 1784647920,
                "headline": "WST Likely to Beat Q2 Earnings Estimates: How to Play the Stock?"
              },
              {
                "id": 140973584,
                "url": "https://finnhub.io/api/news?id=16836b16b30266ddee8f327aa9d7b895752a5d1fd7496fd5c676215fdc6e4ee3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.",
                "category": "company",
                "datetime": 1784647860,
                "headline": "Omnicell to Report Q2 Earnings: OmniSphere in Focus"
              },
              {
                "id": 140971931,
                "url": "https://finnhub.io/api/news?id=893e8bb7b41a606d4a508201130b3480b11bfd298966a40792889fd1dd974627",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GE HealthCare's MIM Anyware offers secure browser-based imaging access to streamline workflows, collaboration and clinical decision-making.",
                "category": "company",
                "datetime": 1784645280,
                "headline": "GEHC Launches MIM Anyware for Secure Remote Imaging Collaboration"
              },
              {
                "id": 140971621,
                "url": "https://finnhub.io/api/news?id=ecc1da10ef106529290939101533f8a9832eadb8bd45283aaf71baea5eb03546",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Wall Street closed lower on Monday, pulled down by healthcare and industrial stocks.",
                "category": "company",
                "datetime": 1784640360,
                "headline": "Stock Market News for July 21, 2026"
              },
              {
                "id": 140971999,
                "url": "https://finnhub.io/api/news?id=332614d04f934331b6fc86cdc065aae05629a2376bc4c6ae936078201a21fc45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Besides Wall Street's top-and-bottom-line estimates for West Pharmaceutical (WST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.",
                "category": "company",
                "datetime": 1784639708,
                "headline": "Curious about West Pharmaceutical (WST) Q2 Performance? Explore Wall Street Estimates for Key Metrics"
              },
              {
                "id": 140962292,
                "url": "https://finnhub.io/api/news?id=d24c4fe2b5991843e4a8f72514f648c4b4214b09dcdb126e31ec51daa60783bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MMSI vs. WST: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1784562005,
                "headline": "MMSI vs. WST: Which Stock Should Value Investors Buy Now?"
              },
              {
                "id": 140961057,
                "url": "https://finnhub.io/api/news?id=7b57cd626dbf5494bbcf5873b3e42358e0db50e5d14043ee30cf4dd6a6200c55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.",
                "category": "company",
                "datetime": 1784558520,
                "headline": "Align Technology to Report Q2 Earnings: Clear Aligner Segment in Focus"
              },
              {
                "id": 140960847,
                "url": "https://finnhub.io/api/news?id=81a8003193de79a3dbfb4e8aa9044d29e2a2203770ac8a44b4e0a51c3b594d32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.",
                "category": "company",
                "datetime": 1784555640,
                "headline": "Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S."
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 5,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.5,
            "source_article_count": 93,
            "discarded_article_count": 71
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.3,
        "grade": "較差",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 726833.3333333334,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 480260,
              "avg_vol_20": 769090,
              "avg_vol_30": 726833.3333333334,
              "range_pct_10": 0.0458467064831646,
              "range_pct_20": 0.17522147205632013,
              "range_pct_30": 0.17522147205632013,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.6607567071772529,
              "dist_to_20d_high": 0.10209844559585499,
              "down_shrink_days": 4,
              "breakout_level_20d": 386,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.2616500474806446
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 0.8,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 1.9063158198447734,
              "turnoverUsdM": 65.58869159999999,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.WST",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 333.3758,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2.5,
              "rsi_score": 3,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.8,
            "take_profit_price": 363.9195,
            "target_multiplier": 1.9,
            "technical_strength": 1.75,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.3114301281954261,
          "stopLossPercent": 3.8126316396895468,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 6.6071,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.91
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 2.23
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0989
    },
    "kdj": {
      "d": 46.48,
      "j": 9.01,
      "k": 33.99,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 69.05
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 7762460,
      "recentSlope": -136964,
      "previousSlope": 333300
    },
    "rsi": 62.24,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 344.5397,
      "position": "SAR喺價下",
      "distancePct": 0.59,
      "previousTrend": "上升"
    },
    "ma50": 346.321,
    "macd": {
      "macd": 0.5855548549180298,
      "trend": "中性偏多",
      "signal": 0.9183416955148809,
      "histogram": -0.33278684059685104
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 345.7676,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 3
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.26,
      "score": 2,
      "avgVolume": 740917,
      "currentVolume": 189240
    },
    "derived": {
      "ma20": 346.1655,
      "ma50": 346.321,
      "prevClose": 346.61,
      "avgVolume10": 450984,
      "avgVolume20": 740917,
      "changePercent": -0.01,
      "avgVolumeForScore": 740917
    },
    "ma_cross": {
      "ma20": 346.1655,
      "ma50": 346.321,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "下穿",
      "score": 2,
      "prevMa20": 346.798,
      "prevMa50": 345.6792,
      "spreadPct": 0.04,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 330.5128,
      "upper": 361.8182,
      "position": "上半部"
    },
    "rsi_short": 30.07,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.26
    }
  }
}

Raw metrics JSON

 
{
  "close": 346.59,
  "volume": 189240,
  "changePercent": -0.01
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.